Cargando…
Improved Protein Kinase C Affinity through Final Step Diversification of a Simplified Salicylate-Derived Bryostatin Analog Scaffold
[Image: see text] Bryostatin 1, in clinical trials or preclinical development for cancer, Alzheimer’s disease, and a first-of-its-kind strategy for HIV/AIDS eradication, is neither readily available nor optimally suited for clinical use. In preceding work, we disclosed a new class of simplified bryo...
Autores principales: | Wender, Paul A., Staveness, Daryl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334251/ https://www.ncbi.nlm.nih.gov/pubmed/25238640 http://dx.doi.org/10.1021/ol502492b |
Ejemplares similares
-
Computer-Guided Design, Synthesis, and Protein Kinase
C Affinity of a New Salicylate-Based Class of Bryostatin Analogs
por: Wender, Paul A., et al.
Publicado: (2014) -
Simplified Bryostatin Analogues Protect Cells from
Chikungunya Virus-Induced Cell Death
por: Staveness, Daryl, et al.
Publicado: (2016) -
Bryostatin analog: improving on Nature's design
por: Boger, Dale
Publicado: (2012) -
“Picolog,” a Synthetically-Available Bryostatin Analog, Inhibits Growth of MYC-Induced Lymphoma In Vivo
por: DeChristopher, Brian A., et al.
Publicado: (2012) -
Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
por: Marsden, Matthew D., et al.
Publicado: (2018)